Loading stock data…
QTRX
$2.80-0.03 (-0.88%)
Market ClosedLast close May 11
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quanterix Corporation in the Healthcare sector is trading at $2.80. The stock is currently near its 52-week low of $2.56, remaining 48.4% below its 200-day moving average. Technical signals show neutral RSI of 39 and bullish MACD crossover, explaining why QTRX maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.80
Potential Upside
5%
Whystock Fair Value$2.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Hold
Mean target$5.33+90.5%
Range$4.00 – $7.00
Fundamentals
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Si...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$153.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.23%
Volume
Today's trading volume
3.15M
Recent News
Tempus AI Expands Beyond Oncology With New Alzheimer’s Blood Test Alliance
Tempus AI (NasdaqGS:TEM) and Lucent Diagnostics, a Quanterix company, are teaming up to bring an AI-enabled care pathway and blood test for Alzheimer's detection into clinical workflows. The collaboration centers on integrating the LucentAD Complete blood-based biomarker panel into Tempus's Next platform for use by neurologists. The partnership extends Tempus AI's reach beyond oncology into neurology and broader precision medicine applications. Tempus AI, trading at around $49.43 per share,...
Quanterix (QTRX) Q1 2026 Earnings Transcript
Need a quote from a Motley Fool analyst? Joshua Young: Thank you, Preyila, and good afternoon, everybody. With me on today's call are Everett Cunningham, Quanterix' President and CEO; and Vandana Sriram, Quanterix' Chief Financial Officer.
Quanterix Q1 Earnings Call Highlights
Quanterix (NASDAQ:QTRX) reported first-quarter 2026 revenue of $36.4 million, up 20% year-over-year, as leadership outlined operational and commercial changes aimed at improving execution in a challenging end-market backdrop. The company also highlighted stepped-up investment in its Alzheimer’s diag
Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates
Quanterix (QTRX) delivered earnings and revenue surprises of -25.81% and -0.67%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The Quanterix (QTRX) Story Is Shifting After The Latest Fair Value Reset
Quanterix is back in focus after analysts reset their fair value estimate from US$7.33 to US$5.33, a cut of about 27% that reframes what they see as a central case for the stock. The latest research links this move directly to a refreshed view of execution risk, with bulls and bears splitting over whether the lower target adds caution or signals deeper concern. As you read on, you will see how these shifting price targets can help you track the evolving story around Quanterix. Analyst Price...